Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
IDEAYA Biosciences is advancing IDE892 into monotherapy expansion as the investigational PRMT5 inhibitor targets MTAP-deleted lung and pancreatic cancers. Representative image.
Pharma & Biotech

What IDEAYA Biosciences’ IDE892 expansion means for MTAP-deleted cancers

IDEAYA advances IDE892 into expansion after reaching target exposure, but clinical response and safety data remain the decisive test.

Read More
A clinician examines atopic dermatitis symptoms as Bambusa Therapeutics reports preliminary proof-of-concept results for investigational bispecific antibody BBT001. Representative image.
Pharma & Biotech

Could BBT001 quarterly dosing differentiate Bambusa in the atopic dermatitis biologics market?

Bambusa’s BBT001 produced an early atopic dermatitis signal, but larger trials must confirm safety, durability and quarterly dosing.

Read More
Laboratory research into next-generation obesity treatments highlights Ascletis Pharma Inc.’s preclinical ASC37 triple peptide agonist, which produced greater weight loss than tirzepatide in a diet-induced obese mouse study. Representative image.
Pharma & Biotech

Can Ascletis ASC37 become a once-monthly triple agonist for obesity?

Ascletis says ASC37 beat tirzepatide in obese mice, but human dosing, safety and durability remain untested ahead of a planned U.S. IND.

Read More
KMM Group targets next growth phase with RS2 Healthcare Partners capital and new CEO
Medical Devices & Diagnostics

Why RS2 Healthcare Partners is backing KMM Group’s precision medtech manufacturing platform

RS2 Healthcare Partners invests in KMM Group and appoints J. Mark King as CEO to scale precision medical device manufacturing.

Read More
ARTHEx Biotech’s ATX-01 preclinical research examines whether systemic RNA therapy can reach the brain and improve DM1-related molecular and behavioral abnormalities. Representative image.
Pharma & Biotech

ARTHEx Biotech reports ATX-01 brain activity in preclinical myotonic dystrophy study

ARTHEx Biotech reports peer-reviewed preclinical evidence that ATX-01 reaches the brain and improves DM1-related behavior in mice.

Read More
Dassault Systèmes’ proposed $1.8 billion acquisition of ArisGlobal highlights the growing strategic value of AI-enabled pharmacovigilance, regulatory and life sciences compliance software. Representative image.
Medical Devices & Diagnostics

What the Dassault Systèmes ArisGlobal acquisition means for pharmacovigilance software

Dassault Systèmes is buying ArisGlobal for up to $2bn, betting AI-driven safety and regulatory software can revive life sciences growth.

Read More
Lundbeck’s investigational orexin 2 receptor agonist Lu AH69593 has received FDA Fast Track designation as competition intensifies to develop new narcolepsy treatments targeting sleep-wake regulation. Representative image.
Pharma & Biotech

Lundbeck has FDA Fast Track status for Lu AH69593, but can it catch the narcolepsy orexin leaders?

Lundbeck’s Lu AH69593 gains FDA Fast Track status, but its Phase 1 narcolepsy programme enters an increasingly competitive orexin field.

Read More
Sentante’s CE-marked endovascular robotic platform combines catheter control, force sensing, medical imaging and procedural data capture to build a foundation for future physical AI-assisted vascular interventions. Representative image.
Medical Devices & Diagnostics

What Sentante’s physical AI strategy means for remote endovascular surgery in Europe

Sentante is using its CE-marked endovascular robot to capture force, motion and imaging data, but its clinical AI value still needs proof.

Read More
Orbiva and Articura plan to develop a localized healthcare AI and AIoT ecosystem supporting hospital data integration, remote patient monitoring and digital health services in Indonesia. Representative image.
Medical Devices & Diagnostics

Home Control’s Orbiva signs Indonesia healthcare AI MOU with Articura

Orbiva and Articura plan localized healthcare AI in Indonesia, but validation, data governance and definitive commercial terms remain decisive.

Read More
A woman experiencing menopause-related fatigue and discomfort, as Bonerge Lifescience launches a clinical study evaluating EquoYouth S-equol for potential menopause symptom relief. Representative image.
Pharma & Biotech

Can Bonerge’s EquoYouth S-equol study strengthen evidence for menopause relief?

Bonerge Lifescience begins an EquoYouth S-equol menopause study as researchers test whether new data can strengthen a contested supplement case.

Read More